CA2480666C - Tnp-470 polymer conjugates and use thereof - Google Patents
Tnp-470 polymer conjugates and use thereof Download PDFInfo
- Publication number
- CA2480666C CA2480666C CA2480666A CA2480666A CA2480666C CA 2480666 C CA2480666 C CA 2480666C CA 2480666 A CA2480666 A CA 2480666A CA 2480666 A CA2480666 A CA 2480666A CA 2480666 C CA2480666 C CA 2480666C
- Authority
- CA
- Canada
- Prior art keywords
- tnp
- polymer
- conjugate
- tumor
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/56—Acrylamide; Methacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37179102P | 2002-04-11 | 2002-04-11 | |
| US60/371,791 | 2002-04-11 | ||
| US41470502P | 2002-09-30 | 2002-09-30 | |
| US60/414,705 | 2002-09-30 | ||
| PCT/US2003/010976 WO2003086382A1 (en) | 2002-04-11 | 2003-04-10 | Tnp-470 polymer conjugates and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2480666A1 CA2480666A1 (en) | 2003-10-23 |
| CA2480666C true CA2480666C (en) | 2012-03-06 |
Family
ID=29254460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2480666A Expired - Lifetime CA2480666C (en) | 2002-04-11 | 2003-04-10 | Tnp-470 polymer conjugates and use thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US7332523B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1494662B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4514455B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2003230852B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2480666C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2398381T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003086382A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030100605A1 (en) * | 2001-05-15 | 2003-05-29 | Grupp Stephan A. | Methods of treating cancer with angiogenesis inhibitors |
| CA2480809A1 (en) * | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| JP4514455B2 (ja) * | 2002-04-11 | 2010-07-28 | チルドレンズ メディカル センター コーポレーション | Tnp−470ポリマー複合体及びその使用 |
| US20080248030A1 (en) * | 2005-02-02 | 2008-10-09 | Children's Medical Center Corporation | Method of Treating Angiogenic Diseases |
| NZ560712A (en) * | 2005-02-17 | 2010-12-24 | Synta Pharmaceuticals Corp | (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders |
| JP2010531896A (ja) | 2007-06-26 | 2010-09-30 | チルドレンズ メディカル センター コーポレーション | 治療的投与のためのMetAP−2阻害剤ポリマーソーム |
| WO2009036108A1 (en) * | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
| US9446150B2 (en) | 2007-10-09 | 2016-09-20 | Washington University | Particles for imaging |
| WO2009049089A1 (en) | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
| BRPI0820229A2 (pt) * | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| WO2009141823A2 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases |
| EP2300021A4 (en) | 2008-05-22 | 2014-10-08 | Univ Ramot | CONJUGATE OF A POLYMER, ANTI-ANGIOGENESE AGENT AND TARGETING REST, AND USES THEREOF FOR THE TREATMENT OF BONE-RELATED ANGIOGENESIS STATES |
| EP2307032A4 (en) * | 2008-05-22 | 2014-08-20 | Univ Ramot | NEW CONJUGATES OF POLYMERS WITH A THERAPEUTIC AGENT AND AN ANGIOGENESIS TARGETING PART CONTAINED THEREOF, AND USES IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS |
| CA2768149A1 (en) * | 2009-07-14 | 2011-01-20 | Lucia Irene Gonzalez | Stereoisomer peptides and their polymer conjugates for hiv disease |
| US8715986B2 (en) * | 2009-10-29 | 2014-05-06 | Lucia Irene Gonzalez | Stereoisomer peptides, ligand-targeted multi- stereoisomer peptide polymer conjugates, and uses thereof |
| US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
| US9764043B2 (en) | 2009-12-17 | 2017-09-19 | Washington University | Antithrombotic nanoparticle |
| EP2558072B1 (en) | 2010-04-15 | 2018-09-26 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
| US20130137831A1 (en) * | 2010-05-25 | 2013-05-30 | John S. Petersen | Optimized drug conjugates |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| WO2011150022A2 (en) * | 2010-05-25 | 2011-12-01 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| IN2014MN01819A (cg-RX-API-DMAC7.html) | 2012-03-05 | 2015-07-03 | Univ Ramot | |
| EP3574922B1 (en) | 2013-04-10 | 2021-09-15 | Syndevrx, Inc. | Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity |
| EP3020114B1 (en) | 2013-07-11 | 2017-05-17 | General Electric Company | Grid power factor control system |
| TW201636342A (zh) | 2014-12-19 | 2016-10-16 | 武田藥品工業有限公司 | 煙黴醇衍生物 |
| KR102849342B1 (ko) | 2015-12-10 | 2025-08-21 | 신데브알엑스, 인크. | 푸마길롤 유도체 및 그의 다형체 |
| AU2017206718B2 (en) | 2016-01-11 | 2021-09-30 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| KR20200096939A (ko) * | 2017-12-06 | 2020-08-14 | 제넨테크, 인크. | 면역조직화학을 위한 합성 대조군 |
| US11612577B2 (en) | 2018-10-26 | 2023-03-28 | Syndevrx, Inc. | Biomarkers of METAP2 inhibitors and applications thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8500209D0 (en) * | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
| US5164410A (en) * | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| EP0359036B1 (en) * | 1988-09-01 | 1997-03-26 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives |
| US5180738A (en) * | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
| US5166172A (en) * | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| US5290807A (en) * | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| US6017954A (en) * | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| EP0415294A3 (en) * | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
| DE69714230T2 (de) * | 1996-03-06 | 2003-03-27 | Tsumura & Co., Tokio/Tokyo | Neue iridoidderivate und neovaskularisations-inhibitoren die diese als aktviven inhaltstoff enthalten |
| US6225478B1 (en) * | 1997-03-05 | 2001-05-01 | Tsumura & Co. | Iridoid derivatives and neovascularization inhibitors containing the same as active ingredient |
| AU1820400A (en) | 1999-11-17 | 2001-05-30 | School Of Pharmacy, University Of London, The | Conjugates of hpma copolymer and ellipticin |
| WO2001097776A1 (fr) | 2000-06-22 | 2001-12-27 | Takeda Chemical Industries, Ltd. | Composition médicamenteuse contenant un polymère |
| ATE552859T1 (de) * | 2000-09-13 | 2012-04-15 | Praecis Pharm Inc | Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden |
| EP1330447A2 (en) * | 2000-11-01 | 2003-07-30 | Praecis Pharmaceuticals Incorporated | Peptides as met-ap2 inhibitors |
| US6548477B1 (en) * | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US6919307B2 (en) | 2000-11-01 | 2005-07-19 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| JP4514455B2 (ja) * | 2002-04-11 | 2010-07-28 | チルドレンズ メディカル センター コーポレーション | Tnp−470ポリマー複合体及びその使用 |
| CA2480809A1 (en) * | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| KR20060130077A (ko) * | 2003-12-29 | 2006-12-18 | 프래시스 파마슈티컬즈 인코포레이티드 | 메티오닌 아미노펩티다제-2 의 저해제 및 이의 용도 |
-
2003
- 2003-04-10 JP JP2003583402A patent/JP4514455B2/ja not_active Expired - Fee Related
- 2003-04-10 WO PCT/US2003/010976 patent/WO2003086382A1/en not_active Ceased
- 2003-04-10 AU AU2003230852A patent/AU2003230852B2/en not_active Ceased
- 2003-04-10 CA CA2480666A patent/CA2480666C/en not_active Expired - Lifetime
- 2003-04-10 ES ES03723958T patent/ES2398381T3/es not_active Expired - Lifetime
- 2003-04-10 US US10/511,009 patent/US7332523B2/en not_active Expired - Lifetime
- 2003-04-10 EP EP03723958A patent/EP1494662B1/en not_active Expired - Lifetime
-
2004
- 2004-02-19 US US10/783,986 patent/US6949584B2/en not_active Expired - Lifetime
-
2005
- 2005-07-20 US US11/185,538 patent/US20060020024A1/en not_active Abandoned
-
2007
- 2007-12-18 US US11/958,688 patent/US20080112919A1/en not_active Abandoned
-
2008
- 2008-10-09 AU AU2008229857A patent/AU2008229857A1/en not_active Abandoned
- 2008-12-02 US US12/326,134 patent/US20090176874A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6949584B2 (en) | 2005-09-27 |
| US20060020024A1 (en) | 2006-01-26 |
| AU2003230852A1 (en) | 2003-10-27 |
| ES2398381T3 (es) | 2013-03-15 |
| WO2003086382A1 (en) | 2003-10-23 |
| AU2008229857A1 (en) | 2008-10-30 |
| AU2003230852B2 (en) | 2008-07-10 |
| US20080112919A1 (en) | 2008-05-15 |
| US7332523B2 (en) | 2008-02-19 |
| CA2480666A1 (en) | 2003-10-23 |
| JP2005529870A (ja) | 2005-10-06 |
| EP1494662B1 (en) | 2012-11-28 |
| EP1494662A4 (en) | 2006-07-19 |
| EP1494662A1 (en) | 2005-01-12 |
| US20090176874A1 (en) | 2009-07-09 |
| US20040229945A1 (en) | 2004-11-18 |
| JP4514455B2 (ja) | 2010-07-28 |
| US20050169881A1 (en) | 2005-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7332523B2 (en) | TNP-470 polymer conjugates and use thereof | |
| US20080248030A1 (en) | Method of Treating Angiogenic Diseases | |
| Satchi-Fainaro et al. | Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 | |
| Chytil et al. | HPMA copolymer–drug conjugates with controlled tumor‐specific drug release | |
| Etrych et al. | HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity | |
| Yang et al. | Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates | |
| Bao et al. | A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy | |
| Iyer et al. | Exploiting the enhanced permeability and retention effect for tumor targeting | |
| Yang et al. | FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy | |
| Chu et al. | Cathepsin B-sensitive polymers for compartment-specific degradation and nucleic acid release | |
| Pan et al. | Efficiency of high molecular weight backbone degradable HPMA copolymer–Prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats | |
| KR20150001710A (ko) | In Vivo 핵산 전달용 폴리(아크릴레이트) 고분자 | |
| CA2739757A1 (en) | Hpma - docetaxel or gemcitabine conjugates and uses therefore | |
| EP4260874A1 (en) | Cleavable polymer drug conjugates | |
| WO2009036108A1 (en) | Methods and compositions for inhibiting vascular leakage | |
| Etrych et al. | Comparison of the pharmacological and biological properties of HPMA copolymer-pirarubicin conjugates: A single-chain copolymer conjugate and its biodegradable tandem-diblock copolymer conjugate | |
| Zhou et al. | Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel | |
| Wei et al. | Disulfide bonds as a molecular switch of enzyme-activatable anticancer drug precise release for fluorescence imaging and enhancing tumor therapy | |
| Hanahan | ll, 2002, provisional application No. 60/414.705, Antoine, N. et al., AGM-1470, a potent angiogenesis inhibitor. filed on Sep. 30, 2002. prevents the entry of normal but not transformed endothelial cells | |
| WO2020218390A1 (ja) | 結合体、及び癌治療剤 | |
| RO138087A2 (ro) | Conjugate polimerice pe bază de poli(2-izopropenil-2-oxazolină) şi doxorubicină pentru imuno-chimio-terapia cancerului şi procedeu de obţinere al acestora | |
| HK1194691A (en) | Poly(acrylate) polymers for in vivo nucleic acid delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20230411 |